Tag: drug-delivery
Halozyme Stock Analysis: Buy or Sell? Valuation, Debt & Margins
Halozyme Therapeutics (HALO) is rated HOLD as strong ENHANZE growth and margins are balanced by a rich valuation and meaningful debt. The stock already prices in much of the platform’s success, leaving limited room for error if cash flow or EPS growth slips.